Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20564811 | 1.00 | RIPK1 (0.41) | RIPK1HCRTR2SLC6A9HCRTR1HTR1A | |
| SCHEMBL20564810 | 0.88 | RIPK1 (0.41) | RIPK1HCRTR2SLC6A9HCRTR1HTR1A | |
| SCHEMBL21867148 | 0.88 | RIPK1 (0.41) | RIPK1HCRTR2SLC6A9HCRTR1HTR1A | |
| SCHEMBL20565656 | 0.83 | OPRM1 (0.40) | RIPK1HCRTR2HCRTR1HTR1AGPBAR1 | |
| SCHEMBL21867146 | 0.83 | OPRM1 (0.40) | RIPK1HCRTR2HCRTR1HTR1AGPBAR1 | |
| SCHEMBL20564809 | 0.83 | RIPK1 (0.51) | RIPK1HCRTR2SLC6A9HCRTR1HTR1A | |
| SCHEMBL28419743 | 0.77 | RIPK1 (0.40) | RIPK1HCRTR2SLC6A9HCRTR1HTR1A | |
| SCHEMBL21867154 | 0.75 | SLC6A9 (0.38) | RIPK1HCRTR2SLC6A9HCRTR1HTR1A | |
| SCHEMBL20564613 | 0.75 | SLC6A9 (0.38) | RIPK1HCRTR2SLC6A9HCRTR1HTR1A | |
| SCHEMBL20564609 | 0.75 | SLC6A9 (0.38) | RIPK1HCRTR2SLC6A9HCRTR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885HCRTR2 4856/4885SLC6A9 4727/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885HCRTR2 4856/4885SLC6A9 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.